Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02012777 · ClinicalTrials.gov registry record · Phase 1
Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease
A Phase 1 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02012777 is a Phase 1 study that was terminated before completion, run by University of Miami. The registered enrollment target is 9 participants.
The verdict
NCT02012777, a Phase 1 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Propanolol is a beta blocker which has been found to inhibit the ability of epinephrine to upregulate sickle red cell adhesion to laminin and endothelial cells in vitro. The purpose of this pilot study is to administer one dose of propanolol to children with sickle cell disease and to measure pre and post dose red cell adhesion. The hypothesis is that a single dose of propanolol will decrease red cell adhesion to laminin and endothelial cells as compared to baseline.
Interventions
- DRUG propranolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-04-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02012777
The ClinicalTrials.gov registry entry for NCT02012777 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which propranolol is the first listed.
NCT02012777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02012777 about?
NCT02012777 is a clinical study titled "Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease". Propanolol is a beta blocker which has been found to inhibit the ability of epinephrine to upregulate sickle red cell adhesion to laminin and endothelial cells in vitro. The purpose of this pilot study is to administer one dose of propanolol to children with sickle cell disease and to measure pre an...
What is the current status of trial NCT02012777?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2010-06. Estimated completion is 2013-04-03.
What interventions are being tested in trial NCT02012777?
The interventions under investigation include: propranolol (DRUG).
Who is sponsoring clinical trial NCT02012777?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.